JP Morgan Chase’s Achieve Life Sciences QUIT Stock Holding History

JP Morgan Chase’s Portfolio QUIT Stock Details QUIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$201K	Buy	32,289 +32,270	+169,842%	+$154K	﹤0.01%	5619
2026 Q1	$51	Hold	19	–	–	﹤0.01%	7358
2025 Q4	$94	Hold	19	–	–	﹤0.01%	7217
2025 Q3	$60	Sell	19 -2,241	-99%	-$6.15K	﹤0.01%	7209
2025 Q2	$5.11K	Sell	2,260 -26,003	-92%	-$74.1K	﹤0.01%	6414
2025 Q1	$75.5K	Sell	28,263 -31,002	-52%	-$96.4K	﹤0.01%	5705
2024 Q4	$209K	Buy	59,265 +44,311	+296%	+$201K	﹤0.01%	5456
2024 Q3	$70.9K	Buy	14,954 +277	+2%	+$1.26K	﹤0.01%	5849
2024 Q2	$69K	Buy	+14,677	New	+$70.7K	﹤0.01%	5718
2023 Q2	–	Sell	-250	Closed	-$1.7K	–	6870
2023 Q1	$1.7K	Buy	+250	New	+$1.19K	﹤0.01%	6469
2019 Q3	–	Sell	-60	Closed	-$2K	–	5685
2019 Q2	$2K	Buy	+60	New	+$4.24K	﹤0.01%	5681
2016 Q4	–	Hold	0	–	–	–	4985
2016 Q3	–	Hold	0	–	–	–	4508
2016 Q2	–	Hold	0	–	–	–	4745

Other funds holding QUIT

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

JP Morgan Chase's QUIT Position: Q2 2026 in Review

JP Morgan Chase increased its Achieve Life Sciences (QUIT) stake by 169,842% in Q2 2026, buying an estimated $154K and bringing the position to 32,289 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #5619.

JP Morgan Chase first reported a position in QUIT in Q2 2019 and has held it in 11 quarters since. The position peaked at $209K in Q4 2024. 112 funds tracked by Wall St. Rank hold QUIT as of Q2 2026.

JP Morgan Chase held 32,289 shares of Achieve Life Sciences worth $201K as of Q2 2026.
JP Morgan Chase bought 32,270 Achieve Life Sciences shares in Q2 2026, an estimated $154K.
Achieve Life Sciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5619 holding.
JP Morgan Chase first reported a position in Achieve Life Sciences in Q2 2019 and has held it in 11 quarters since.
JP Morgan Chase's Achieve Life Sciences position peaked at $209K in Q4 2024.
112 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.